Description
Retatrutide
Research Areas
Retatrutide is being actively investigated across the following areas:
- Weight management & obesity
- Glucose regulation
- Insulin sensitivity
- Metabolic syndrome
- Type 2 diabetes
- Non-alcoholic fatty liver disease
- Dyslipidaemia
- Energy expenditure & thermogenesis
How It Works
Unlike single or dual-agonist peptides, retatrutide binds to three distinct metabolic receptors at the same time. This multi-pathway approach is what sets it apart from compounds like semaglutide or tirzepatide, and is the basis for the more pronounced metabolic effects observed in clinical trials.
Enhances satiety and reduces appetite. Promotes insulin secretion and supports blood glucose regulation.
Improves insulin sensitivity and secretion. Plays a key role in glucose-dependent metabolic control.
Increases energy expenditure and metabolic rate. Supports fat mobilisation and thermogenic activity.
Clinical Research Context
Retatrutide is currently in Phase 2 clinical trials. Published data in the New England Journal of Medicine found that 100% of subjects receiving doses of 8mg and 12mg per week experienced significant weight loss — with reductions of up to 24% of body weight over 48 weeks.
For comparison, semaglutide (Ozempic/Wegovy) achieved approximately 17.4% weight reduction over 68 weeks, and tirzepatide (Mounjaro) achieved around 20.9% over 72 weeks. Retatrutide’s results are notable both in magnitude and in the speed at which they were achieved.
As with similar peptides, mild to moderate gastrointestinal effects have been reported. Clinical protocols typically begin at 2mg/week, with gradual dose escalation to 4mg, 8mg, or 12mg over several weeks.
Product Information
| Format | Lyophilised powder |
| Available sizes | 5mg / 10mg per vial |
| Purity | ≥99% (third-party tested, COA available) |
| Molecular formula | C₂₂₁H₃₄₂N₄₆O₆₈ |
| Molecular weight | 4,860 g/mol |
| CAS number | 2381089-83-2 |
| Storage (lyophilised) | −20°C, away from light and moisture |
| Storage (reconstituted) | 2–8°C, use within 7 days |
Frequently Asked Questions
Yes. Retatrutide is not a controlled substance and is legal to purchase in the UK for research purposes. It is not licensed for human consumption or medical use.
In clinical trials, retatrutide produced weight loss results significantly greater than semaglutide — up to 24% over 48 weeks versus semaglutide’s approximately 17.4% over 68 weeks. The triple-receptor mechanism is considered the primary reason for this difference.
No. Retatrutide is currently in Phase 2 clinical trials and is not yet approved as a prescription medicine anywhere in the world. It is available for research purposes only.
As a lyophilised powder, store at −20°C away from direct light and moisture. Once reconstituted, refrigerate at 2–8°C and use within 7 days.
Each batch is independently tested by a third-party laboratory. A COA confirming purity and identity is available on request or in the product image gallery.
Legal & Compliance Notice
This product is intended strictly for laboratory research use only and is not approved for human or veterinary use. It is not a drug, dietary supplement, food additive, cosmetic, injectable, or therapeutic agent, and must not be used in or on humans or animals.
- The buyer assumes full responsibility for the safe and lawful handling, storage, and use of this product.
- Primal Mind & Body assumes no liability for misuse, injury, loss, or legal consequences arising from improper or unauthorised use.
- It is the buyer’s responsibility to ensure that purchase and possession of this product is legal in their jurisdiction.
- This product must not be resold for the purpose of human consumption.
For Research Use Only · Not for Human or Veterinary Use · Not for Diagnostic or Therapeutic Applications
Full Terms & Conditions for our Peptide products can be found here https://www.primalmindbody.co.uk/research-peptide-terms-conditions/
Reviews
There are no reviews yet.